Restrictions curbing success of pharma groups of all sizes
September 30, 2020 | 11:00
Amid a lacklustre picture in the market, domestic pharma giants are attempting to cut costs to weather the storm of COVID-19, while multinational corporations like F. Hoffmann-La Roche, AstraZeneca, and Novartis are making new preparations.
Mobile Version